Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants under 1 year of age and a significant cause of serious respiratory illness in elderly adults and immunocompromised patients. In the United States, RSV infects nearly all children by age 2 and hospitalizes approximately 58,000–80,000 children under 5 each year. Adults over 65 account for an additional 60,000–160,000 hospitalizations annually. RSV circulates in predictable seasonal waves from October through March in temperate climates, creating peak demand on pediatric inpatient units during this period.
For nurses, RSV matters because early recognition of respiratory distress — especially in young infants — and timely intervention with positioning, oxygen, and high-flow nasal cannula can prevent respiratory failure. This reference covers everything you need: pathophysiology, high-risk populations, age-specific presentation, nursing assessment, diagnostics, interventions, medications including the new nirsevimab prophylaxis, isolation precautions, complications, discharge education, and six NCLEX-style practice questions. Use this alongside the vital signs by age reference and the nursing lab values cheat sheet for full RSV patient management.
RSV at a glance
| Parameter | Key facts |
|---|---|
| Pathogen | Respiratory syncytial virus — enveloped, negative-sense single-stranded RNA virus (Pneumoviridae family) |
| Season | October–March (peaks December–February in temperate climates) |
| Primary disease in infants | Bronchiolitis (#1 cause in infants <1 year) and pneumonia |
| High-risk populations | Premature infants (<35 wk GA), infants <6 months, CHD, CLD of prematurity, immunocompromised, adults ≥65 |
| Isolation precautions | Contact + droplet precautions; dedicated equipment; cohorting when possible |
| Key prophylaxis drug | Nirsevimab (Beyfortus) — single-dose IM, approved 2023; replaces palivizumab for most patients |
| First-line respiratory support | High-flow nasal cannula (HFNC) for moderate-severe bronchiolitis — reduces intubation rates |
| Treatments NOT recommended | Bronchodilators and corticosteroids are NOT standard of care for bronchiolitis (AAP guidelines) |
| Priority nursing action | Assess work of breathing: nasal flaring, retractions (intercostal/subcostal), grunting, SpO2, respiratory rate |
| NCLEX alert | Aspirin is CONTRAINDICATED in children <18 years (Reye's syndrome); nirsevimab/palivizumab is prophylaxis, NOT treatment |
Pathophysiology
Viral structure and mechanism of infection
RSV is a member of the Pneumoviridae family and uses its two surface glycoproteins — the fusion (F) protein and the attachment (G) protein — to enter respiratory epithelial cells. The F protein mediates fusion of the viral envelope with the host cell membrane, enabling viral entry. Importantly, the prefusion conformation of the F protein is the primary target of the most effective neutralizing antibodies and is the basis for both nirsevimab (Beyfortus) and the newer RSV vaccines approved for adults.
Unlike influenza, RSV does not undergo major antigenic shift. Antigenic variation exists between the two major subtypes (RSV-A and RSV-B) and accumulates gradually within each subtype, but the change is far less dramatic than influenza’s annual drift. This is why a single-dose monoclonal antibody like nirsevimab can provide a full season of protection.
Bronchiolitis: the key pathological process
In infants and young children, RSV infects the bronchiolar epithelium — the smallest airways. The inflammatory response causes:
- Epithelial cell necrosis and sloughing — the ciliated epithelium lining the bronchioles dies and sheds into the airway lumen
- Peribronchiolar edema and lymphocytic infiltration — the surrounding tissue swells
- Mucus hypersecretion — goblet cells produce excess mucus that mixes with sloughed debris
- Mucus plugging and partial airway obstruction — plugs cause air trapping distal to the obstruction; complete plugs cause atelectasis
- Air trapping — trapped air increases total lung volume, causes hyperinflation visible on chest X-ray, and produces the characteristic prolonged expiratory phase on auscultation
- Ventilation/perfusion (V/Q) mismatch — lung units that are ventilated but not perfused (or perfused but not ventilated) impair gas exchange, driving hypoxemia
The infant airway is particularly vulnerable because the bronchiolar diameter is small — even modest edema produces disproportionate airflow resistance (resistance increases with the fourth power of the radius reduction). This explains why bronchiolitis severity is age-dependent: the younger the infant, the smaller the airways, the greater the physiologic impact of the same degree of inflammation.
Bronchiolitis vs RSV pneumonia
Bronchiolitis is the classic RSV syndrome in infants under 2 years. It is a clinical diagnosis — diffuse inflammation of the small airways with air trapping and expiratory obstruction. Chest X-ray shows hyperinflation and peribronchial thickening.
RSV pneumonia involves extension of infection into the alveoli, producing consolidation similar to bacterial pneumonia. RSV pneumonia is more common in immunocompromised patients and elderly adults. In severe cases, alveolar damage can progress to acute respiratory distress syndrome — see the ARDS nursing reference for management of severe respiratory failure in this context.
Seasonal pattern
RSV follows predictable seasonal peaks: October–March in temperate Northern Hemisphere climates, with December through February representing the highest-risk weeks. The COVID-19 pandemic disrupted normal RSV seasonality — seasons became atypical in 2021–2022 with out-of-season surges. Since 2023, RSV seasonality has largely normalized.
Clinical presentation by age group
RSV produces a spectrum of illness that varies dramatically by age and underlying health status. Recognizing age-specific presentations is essential for nurses triaging patients during RSV season.
| Age group | Typical symptoms | Red flags requiring escalation |
|---|---|---|
| Young infants (<3 months) and premature infants | Rhinorrhea, cough, poor feeding, irritability. May present with apnea as the first or predominant sign — especially in very preterm infants. Fever may be absent or low-grade. Subtle signs of respiratory distress. | Apnea, SpO2 <90%, poor feeding (intake <50% of normal), lethargy, cyanosis. Any apnea episode in an infant <2 months is high-risk and requires cardiorespiratory monitoring. |
| Infants 3–12 months | 2–4 day URI prodrome (rhinorrhea, low-grade fever) followed by worsening cough and increased work of breathing. Classic signs: nasal flaring, intercostal and subcostal retractions, grunting, tachypnea, SpO2 <95%, poor oral intake, audible wheeze. | SpO2 <90%, severe retractions, grunting, cyanosis, apnea, refusal to feed, extreme tachypnea (RR >70/min in infants). |
| Toddlers and older children (1–5 years) | Rhinorrhea, cough, mild wheeze, low-grade fever. Illness is typically milder than in infants. Children with pre-existing reactive airway disease may have significant bronchospasm. | Worsening wheeze unresponsive to bronchodilators, SpO2 <92%, signs of dehydration, persistent high fever suggesting secondary bacterial infection. |
| Immunocompetent adults | URI symptoms — rhinorrhea, nasal congestion, sore throat, low-grade fever, mild cough. Self-limiting; typically resolves in 1–2 weeks. Similar to common cold in most healthy adults. | SpO2 decline, productive cough with purulent sputum (suggests secondary bacterial pneumonia), dyspnea at rest. |
| Adults ≥65 years and immunocompromised | May present with significant lower respiratory tract disease — productive cough, dyspnea, wheezing, or exacerbation of underlying COPD or heart failure. Fever may be blunted. | SpO2 <92%, RR >30/min, confusion (new or worsening), inability to complete sentences, signs of respiratory failure. |
Key teaching point: Infants with RSV do not always look critically ill at first assessment. Work of breathing often worsens with activity (feeding, crying) and may be most pronounced immediately after feeding. Assess before and after feeds, and track trends rather than single-point observations.
Nursing assessment
Respiratory assessment priorities
Assessment of the RSV patient centers on work of breathing and oxygenation status. Perform a structured respiratory assessment at each encounter:
1. Respiratory rate — Compare against age-appropriate norms (see the vital signs by age reference). Tachypnea is often the earliest sign of respiratory distress in infants. Normal infant RR is 30–60/min; RR persistently above 60–70 in an infant is significant.
2. SpO2 — Continuous pulse oximetry monitoring for hospitalized patients. Target SpO2 ≥90–95% (≥95% in high-risk infants including those with CHD or prematurity). SpO2 may be artificially elevated in patients with poor peripheral perfusion — assess waveform quality.
3. Work of breathing signs — assess systematically:
- Nasal flaring — nares widen with each breath; indicates respiratory distress
- Intercostal retractions — skin pulls inward between ribs
- Subcostal retractions — skin pulls inward below the ribcage
- Supraclavicular/suprasternal retractions — indicate more severe distress
- Grunting — audible on expiration; infant is using glottic closure to generate positive end-expiratory pressure (PEEP) and maintain alveolar recruitment. Grunting is a sign of significant respiratory distress.
- Accessory muscle use — sternocleidomastoid, scalene muscle use indicates near-maximal effort
- Head bobbing in infants — the head nods forward with each inspiratory effort, indicating use of the sternocleidomastoid as an accessory muscle; sign of severe distress
4. Auscultation — Expiratory wheeze (from small airway obstruction), inspiratory crackles (from reopening of collapsed airways), prolonged expiratory phase. Breath sounds may be diminished in areas of significant mucus plugging or atelectasis.
5. Feeding tolerance — In infants, feeding is a respiratory stress test. Inability to sustain adequate oral intake indicates respiratory compromise severe enough to interfere with coordination of breathing and sucking/swallowing. Track intake as a percentage of normal feeds; oral intake below 50% of normal is a marker of clinical severity.
6. Hydration status — Assess anterior fontanelle (sunken = dehydration), skin turgor, mucous membrane moisture, urine output (wet diapers), and capillary refill. Tachypnea increases insensible losses while poor feeding decreases intake — dehydration develops quickly.
Red flags requiring immediate escalation
- Apnea (any episode in infant <2 months; recurrent or prolonged in older infants)
- SpO2 <90% on supplemental oxygen or any SpO2 <85%
- Grunting at rest
- Cyanosis
- Altered mental status or extreme lethargy
- Failure to respond to HFNC after 1–2 hours of trial
Diagnostic workup
RSV is primarily a clinical diagnosis in infants with classic bronchiolitis during RSV season. Laboratory and radiologic testing does not change management in most cases. Testing is used when the diagnosis is uncertain, when the patient is being admitted, or when cohorting RSV-positive patients together is logistically important for infection control.
RSV antigen detection test: Nasal swab (nasopharyngeal swab preferred for best sensitivity). Rapid antigen tests provide results in 15–30 minutes. Sensitivity is approximately 80–90% in young children (viral shedding is highest and most reliable in this group) but significantly lower in adults.
PCR (polymerase chain reaction): Higher sensitivity (>95%) across all age groups. Preferred for immunocompromised patients, elderly adults, and when clinical suspicion is high despite a negative antigen test. Multiplex respiratory viral panels can simultaneously test for influenza A/B, RSV, parainfluenza, adenovirus, human metapneumovirus, and SARS-CoV-2 — useful during co-circulation seasons.
Chest X-ray (CXR): Bronchiolitis produces characteristic findings: hyperinflation (flattened diaphragms, increased anterior-posterior diameter), peribronchial thickening (prominent bronchial markings), and patchy atelectasis. CXR is not routinely required for classic bronchiolitis in infants but is indicated when the diagnosis is uncertain, when the patient fails to improve as expected, or when secondary bacterial pneumonia is suspected. Consolidation suggests pneumonia superimposed on bronchiolitis. See the pneumonia nursing reference for pneumonia assessment and management when RSV leads to lower respiratory tract consolidation.
Laboratory studies: Check the nursing lab values cheat sheet for normal ranges. CBC may show lymphocytosis (viral pattern). Serum electrolytes and BUN/creatinine assess hydration status in patients with poor oral intake. Blood gas (ABG or VBG) is reserved for patients with significant respiratory distress or impending respiratory failure.
Nursing interventions
Positioning
Position infants and children with the head of bed elevated at 30–45 degrees to reduce diaphragmatic pressure from abdominal contents and optimize respiratory mechanics. In infants, use an infant seat or wedge positioning system.
Prone positioning is contraindicated in unsupervised infants due to sudden infant death syndrome (SIDS) risk. Prone positioning may be considered in intubated infants in the ICU setting under continuous monitoring, but this is a physician/advanced practice decision — never independently prone an unmonitored infant.
Oxygen therapy
Administer humidified supplemental oxygen to maintain SpO2 at the target level — ≥90–95% for most patients, ≥95% for high-risk infants (premature, CHD). Dry oxygen worsens mucous membrane dryness and increases secretion viscosity.
Oxygen delivery methods by severity:
- Low-flow nasal cannula (LFNC): Flow rates 0.1–2 L/min in infants; appropriate for mild hypoxemia
- Simple face mask or non-rebreather mask: When higher FiO2 needed and HFNC is not yet initiated
- High-flow nasal cannula (HFNC): First-line escalation for moderate-severe bronchiolitis
High-flow nasal cannula (HFNC)
HFNC delivers heated, humidified air/oxygen at flows of 1–2 L/kg/min (up to 8 L/kg/min in some protocols) via large-bore nasal cannula prongs. Mechanisms of benefit in bronchiolitis:
- Reduces nasopharyngeal dead space, improving CO2 washout
- Provides modest positive airway pressure (2–4 cmH2O), splinting open small airways
- Reduces work of breathing, allowing the infant to redirect effort to feeding
Multiple randomized trials and meta-analyses have shown HFNC reduces escalation to ICU and intubation in bronchiolitis. HFNC is now the standard of care for moderate-severe bronchiolitis across pediatric institutions. Monitor for response at 1–2 hours; failure to improve or worsening clinical status after HFNC initiation should prompt escalation and physician notification.
Airway suctioning
Infants are obligate nose-breathers. Nasal secretions significantly worsen airway obstruction and feeding difficulty. Perform gentle nasopharyngeal suctioning before feeds and as needed:
- Use bulb syringe for mild secretions
- Nasopharyngeal catheter suction for copious or thick secretions
- Normal saline nasal drops (1–2 drops per nostril) can loosen secretions before suctioning
- Avoid deep suctioning — it stimulates the vagal reflex and can cause bradycardia and laryngospasm
Hydration and nutrition
Adequate hydration is essential — tachypnea increases insensible fluid losses while illness decreases intake.
- Oral/bottle/breast feeds: Support small, frequent feeds if the infant can tolerate. Limit individual feed duration (e.g., 20–30 minutes) to avoid fatiguing an already-stressed infant.
- Nasogastric tube (NGT) feeds: Insert NGT when oral intake falls below 50–75% of normal. NGT feeds avoid the respiratory stress of bottle feeding while maintaining enteral nutrition.
- IV fluids: Initiate when oral and NGT feeds are insufficient to maintain hydration, or when the infant is too distressed to safely accept any enteral intake. Use isotonic fluids; monitor closely for fluid overload in patients with CHD.
- Monitor urine output: Wet diapers every 4–6 hours is acceptable; a marked reduction in wet diapers over 8 hours indicates significant dehydration.
Fever management
- Acetaminophen: Safe from birth for fever ≥38°C; dose by weight every 4–6 hours
- Ibuprofen: Safe in children ≥6 months; avoid in infants <6 months
- Aspirin: CONTRAINDICATED in all children and adolescents <18 years — risk of Reye’s syndrome (acute hepatic failure and encephalopathy). This is a high-yield NCLEX concept. See the medication rights in nursing reference for additional safety checks.
RSV medications
| Drug/intervention | Class/type | Indication | Nursing considerations |
|---|---|---|---|
| Nirsevimab (Beyfortus) | Long-acting monoclonal antibody targeting RSV prefusion F protein | Prophylaxis: all infants <8 months entering first RSV season; select high-risk children 8–19 months. Single-dose IM injection. FDA approved 2023. | This is prevention, not treatment — does not reduce severity once RSV infection is established. Replace palivizumab for most patients. Give before RSV season begins. Weight-based dosing (50 mg if <5 kg; 100 mg if ≥5 kg). Document in immunization record. Observe 15 min post-injection for hypersensitivity. |
| Palivizumab (Synagis) | Monoclonal antibody (older generation) targeting RSV F protein | Prophylaxis: premature infants <35 wk GA, hemodynamically significant CHD, or CLD of prematurity (when nirsevimab is unavailable or contraindicated). Monthly IM injection October–March, up to 5 doses per season. | Prophylaxis only, NOT treatment. Monthly dosing is critical — missed doses leave the infant unprotected. Largely replaced by nirsevimab since 2023. Expensive; requires prior authorization for most payers. |
| Supplemental oxygen | Respiratory support | SpO2 <90–95%; target ≥95% in high-risk infants. | Use humidified oxygen to prevent airway drying. Titrate to target — avoid excessive O2 in premature infants (retinopathy of prematurity risk at very high concentrations in neonates). Monitor SpO2 continuously. |
| High-flow nasal cannula (HFNC) | Non-invasive respiratory support device | Moderate-severe bronchiolitis with increased work of breathing and/or hypoxemia refractory to low-flow O2. First-line escalation before CPAP or intubation. | Flow rate typically 1–2 L/kg/min, titrated by response. Assess work of breathing at 1–2 hours after initiation. Failure to respond = escalate. Heated and humidified circuit required. Ensure proper cannula sizing (should not occlude nares completely). |
| Ribavirin (aerosolized) | Antiviral (nucleoside analogue) | Severely immunocompromised patients with RSV lower respiratory tract infection (e.g., post-HSCT or SOT). Very limited use. | Teratogenic: pregnant healthcare workers must not administer or enter the room during treatment. Requires negative pressure room and specialized administration equipment. Routine use is not recommended for immunocompetent patients. Monitor for deterioration despite treatment. |
| Bronchodilators (albuterol, racemic epinephrine) | Beta-2 agonist / sympathomimetic | NOT recommended as routine treatment for bronchiolitis (AAP guidelines 2014, reaffirmed). A single-dose trial may be acceptable in select patients but should not be continued unless there is clear clinical improvement. | Do not continue if there is no demonstrable response after a trial dose. May worsen tachycardia. Racemic epinephrine may provide transient improvement but does not alter the disease course or hospitalization length. Do not discharge immediately after epinephrine (observe ≥4 hours for rebound). |
| Corticosteroids (systemic or inhaled) | Anti-inflammatory | NOT recommended for bronchiolitis. Multiple randomized controlled trials (including dexamethasone vs. placebo trials) show no benefit in hospitalization length or outcomes. | Do not administer steroids for bronchiolitis unless there is a clear documented history of reactive airway disease or asthma (not just recurrent wheeze) where a steroid trial is part of the management plan. NCLEX-high-yield: steroids = no benefit in bronchiolitis. |
| Acetaminophen / ibuprofen | Antipyretics / analgesics | Fever ≥38°C; comfort care. | Ibuprofen only for children ≥6 months. Aspirin CONTRAINDICATED in all patients <18 years (Reye's syndrome). Dose by weight. Alternating acetaminophen and ibuprofen every 3 hours is sometimes used for refractory fever — ensure families understand dosing intervals to prevent overdose. |
Isolation precautions
RSV is transmitted via large respiratory droplets (generated by coughing and sneezing) and by direct and indirect contact with contaminated secretions. RSV can survive on hard surfaces for up to 6 hours and on skin for 30 minutes — making contact transmission via hands and fomites a primary route in healthcare settings.
Implement contact + droplet precautions for all patients with confirmed or suspected RSV:
- Gown and gloves for all patient contact (contact precautions)
- Surgical mask when within 6 feet of the patient (droplet precautions)
- Dedicated equipment — stethoscope, thermometer, oximeter probe — stays in the room; do not share between patients
- Cohorting — when multiple RSV-confirmed patients are admitted simultaneously, cohort them in the same ward section to reduce cross-contamination to non-RSV patients and to allow efficient staffing
Hand hygiene
Soap and water is preferred over alcohol-based hand rub (ABHR) for RSV because mechanical washing physically removes viral particles from the skin, including from under fingernails and skin folds. ABHR is effective at inactivating RSV and is acceptable when soap and water is not immediately available — both should be used consistently. Perform hand hygiene:
- Before and after all patient contact
- Before and after glove removal
- After contact with potentially contaminated surfaces in the patient’s environment
Educate families on hand hygiene during their visits and emphasize that RSV spreads on unwashed hands — a caregiver touching their face after handling secretions can self-inoculate, and then spread the virus to the next person or surface they touch.
Isolation precautions should be maintained for the duration of the illness. RSV shedding can persist for 3–8 days in immunocompetent patients and for weeks in immunocompromised individuals.
Complications
Most healthy infants with RSV bronchiolitis recover fully within 1–2 weeks. Complications are more likely in high-risk populations and in infants who present with significant respiratory compromise.
Apnea — The most dangerous complication in young infants, particularly those born prematurely. Apnea may be the presenting sign of RSV in infants under 2–3 months. All infants under 2 months admitted with RSV require continuous cardiorespiratory monitoring. Apnea can precede respiratory failure and requires immediate assessment and response per institutional protocol.
Respiratory failure — Severe bronchiolitis or RSV pneumonia can progress to respiratory failure requiring intubation and mechanical ventilation. Risk factors include age under 6 weeks, prematurity, CHD, CLD, and failure to respond to HFNC. If a patient on HFNC develops worsening work of breathing, rising PaCO2, altered mental status, or persistent SpO2 below 90%, notify the physician immediately and prepare for possible intubation.
Secondary bacterial infections — Disrupted bronchiolar epithelium is susceptible to bacterial co-infection. Common secondary infections include otitis media (very common after RSV in infants — ask about ear pain, increased irritability), bacterial pneumonia (Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae), and — in severe or prolonged illness — sepsis. Monitor for new fever after initial improvement, purulent secretions, or hemodynamic changes. See the sepsis nursing reference for early sepsis recognition and the hour-1 bundle.
Dehydration — A direct complication of increased fluid losses from tachypnea combined with decreased oral intake. Can progress to acute kidney injury if prolonged.
Exacerbation of chronic conditions — RSV is a potent trigger for exacerbation of reactive airway disease and asthma in older children and adults. In adults with COPD or heart failure, RSV lower respiratory tract illness can precipitate acute decompensation. RSV is also recognized as a cause of acute respiratory distress syndrome in severely immunocompromised patients — see the ARDS nursing reference.
Long-term outcomes — RSV bronchiolitis in infancy is associated with increased rates of recurrent wheeze and asthma in early childhood. The causal relationship is debated — it is unclear whether severe RSV causes permanent airway changes or whether infants who develop severe bronchiolitis have pre-existing airway biology that predisposes them to both RSV severity and later atopic disease.
Discharge education
Discharge from inpatient RSV care requires that the infant or child demonstrates sustained SpO2 ≥90–95% on room air, adequate oral intake, and caregivers who are confident in home management and return precautions.
Return precautions — teach families to return immediately for:
- Breathing that looks harder than at discharge (nasal flaring, visible retractions)
- SpO2 below 90% on home monitor (if prescribed)
- Refusal to feed or intake less than half of normal for more than 8 hours
- Fewer than 4 wet diapers in 24 hours
- Any pause in breathing longer than 10–15 seconds (apnea)
- Color change — cyanosis around the lips or fingertips
- Extreme lethargy, difficulty waking, or unresponsiveness
Prevention education
- Nirsevimab (Beyfortus): For infants eligible for prophylaxis, ensure caregivers understand this is a single dose given before RSV season — not a vaccine, but a monoclonal antibody. Works for one season; the infant will need reassessment next season.
- Hand hygiene: The single most effective prevention measure. Thorough handwashing before handling the infant, especially after being in public spaces during RSV season.
- Avoid sick contacts: Keep infants — especially those under 3 months — away from people with cold symptoms during October–March.
- Breastfeeding: Breast milk contains immunoglobulins (including RSV-specific IgA) that provide partial protection against severe RSV illness. Encourage continued breastfeeding throughout illness and after discharge.
- Avoid tobacco smoke exposure: Secondhand smoke exposure impairs mucociliary clearance and dramatically increases RSV severity risk.
- Childcare exposure: Large group childcare increases RSV exposure risk for infants. Families should discuss timing of childcare entry with their pediatrician.
NCLEX practice questions
| # | Question | Correct answer | Rationale |
|---|---|---|---|
| 1 | A 6-week-old infant born at 28 weeks gestation is admitted with RSV bronchiolitis. Which finding requires the nurse to notify the physician immediately?
A. Respiratory rate of 52/min B. SpO2 of 94% on 0.5 L/min nasal cannula C. A 20-second pause in breathing followed by spontaneous resumption D. Three wet diapers in the past 12 hours |
C | A 20-second apneic episode in a premature infant with RSV requires immediate physician notification. Apnea is the most dangerous RSV complication in very young and premature infants and can precede respiratory failure. This infant is at exceptionally high risk: gestational age 28 weeks (very premature) and only 6 weeks of corrected age. A respiratory rate of 52 is within the normal range for infants (30–60/min). SpO2 of 94% on 0.5 L/min nasal cannula is low for a high-risk premature infant (target ≥95%) but is not an acute emergency requiring immediate physician notification the way apnea is — it warrants oxygen titration and reassessment. Three wet diapers in 12 hours is mildly decreased but not a red flag in isolation. |
| 2 | A nurse is educating a parent about palivizumab (Synagis) prescribed for their 3-month-old born at 32 weeks gestation. Which statement by the parent indicates a need for further teaching?
A. "My baby will need a shot every month during RSV season." B. "This medication will treat my baby's RSV if she gets infected." C. "I should call the doctor if my baby develops breathing problems even after the shot." D. "The injections are given October through March." |
B | Palivizumab (Synagis) is prophylaxis, not treatment. It reduces the risk of severe RSV illness but does not treat active RSV infection. A parent who believes it will treat RSV if their child becomes infected has a dangerous misunderstanding — they may delay seeking care. Statements A (monthly injection), C (call if breathing problems develop despite prophylaxis — prophylaxis is not 100% effective), and D (October–March dosing schedule) are all correct. |
| 3 | An 8-month-old with RSV bronchiolitis has a temperature of 38.8°C. The nurse prepares to administer an antipyretic. Which medication is appropriate?
A. Aspirin 81 mg orally B. Ibuprofen 10 mg/kg orally C. Naproxen 5 mg/kg orally D. Codeine 0.5 mg/kg orally |
B | Ibuprofen is appropriate for children ≥6 months at 5–10 mg/kg per dose. Aspirin (A) is contraindicated in all children and adolescents under 18 years due to the risk of Reye's syndrome — a potentially fatal condition causing acute hepatic failure and encephalopathy associated with aspirin use during viral illness. Naproxen (C) is not recommended for pediatric fever management in this age group and is not an approved antipyretic for infants. Codeine (D) is an opioid; it carries risk of respiratory depression and is not used for fever. |
| 4 | A nurse is caring for an 11-month-old with moderate RSV bronchiolitis. The child is on 2 L/min nasal cannula with SpO2 of 88–90% and has visible intercostal retractions. Which intervention should the nurse anticipate initiating next?
A. Systemic dexamethasone B. Nebulized albuterol every 4 hours C. High-flow nasal cannula (HFNC) D. Immediate orotracheal intubation |
C | HFNC is the appropriate next escalation for an infant with moderate-severe bronchiolitis who is not maintaining adequate oxygenation on low-flow nasal cannula. HFNC reduces work of breathing, improves oxygenation, and decreases rates of intubation in bronchiolitis. Dexamethasone (A) is not recommended for bronchiolitis — multiple RCTs show no benefit. Albuterol (B) is not routinely recommended for bronchiolitis per AAP guidelines; routine use is not supported. Immediate intubation (D) would be appropriate only if the infant fails HFNC or presents in acute respiratory failure — it is premature before a HFNC trial. |
| 5 | A nurse is implementing isolation precautions for an infant admitted with RSV. Which action is correct?
A. Airborne precautions with an N95 respirator for all care B. Contact and droplet precautions with gown, gloves, and surgical mask C. Droplet precautions only — gloves are not needed unless blood or body fluid contact is anticipated D. Standard precautions only — RSV is not transmissible in a healthcare setting |
B | RSV requires contact and droplet precautions. Gown and gloves are required for contact precautions (RSV spreads via hand contact with secretions and contaminated surfaces — it survives on hard surfaces up to 6 hours and on skin up to 30 minutes). A surgical mask is required for droplet precautions when within 6 feet of the patient. Airborne precautions with N95 (A) are not required for RSV in routine care; this level of precaution is used for tuberculosis, measles, and varicella, and for aerosol-generating procedures on respiratory viral patients. Droplet precautions alone (C) would miss the significant contact transmission route. Standard precautions alone (D) is incorrect and dangerous. |
| 6 | A nurse is reviewing the medical record of a 4-month-old with confirmed RSV. The patient is an infant born at 34 weeks gestation, now admitted for the second time this RSV season with severe bronchiolitis requiring HFNC. The family asks why their baby "keeps getting so sick" when other babies seem to handle RSV better. Which response by the nurse is most accurate?
A. "RSV is always severe in all infants under 1 year — your baby is just average." B. "Your baby's premature birth means smaller airways and an immune system that had less time to develop before birth, making RSV more dangerous." C. "This is likely a different virus — RSV only causes severe illness once per season." D. "Your baby is probably just more sensitive to all infections; this has nothing to do with prematurity." |
B | Premature infants have two key vulnerabilities to severe RSV: (1) underdeveloped lungs with smaller bronchioles — even mild inflammation produces disproportionate airflow obstruction because airway resistance increases dramatically with small radius reductions; and (2) less transfer of maternal RSV-specific antibodies (most IgG transfer from mother to fetus occurs in the third trimester — infants born at 34 weeks have significantly less passive antibody protection). RSV is not universally severe in all infants (A — severity varies significantly by risk factors). RSV can cause multiple illnesses and re-infections in the same individual within and across seasons (C is incorrect). Prematurity is the most significant single risk factor for severe RSV illness in infants (D is incorrect). |
Summary
RSV is a seasonal respiratory virus that causes the spectrum of illness from mild URI in healthy adults to life-threatening bronchiolitis and respiratory failure in high-risk infants. Nursing priorities are respiratory assessment (work of breathing, SpO2, feeding tolerance), timely escalation to HFNC for moderate-severe bronchiolitis, and prevention of nosocomial spread via contact and droplet precautions. Nirsevimab (Beyfortus) has transformed prophylaxis as a single-season, single-dose option for eligible infants. For NCLEX, remember: bronchodilators and steroids are not standard care for bronchiolitis, aspirin is contraindicated under age 18, and nirsevimab/palivizumab are prophylaxis — not treatment. Compare RSV to other respiratory viruses in the influenza nursing reference and the COVID-19 nursing reference.
Sources: American Academy of Pediatrics (AAP) Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis (2014, reaffirmed 2021); CDC RSV Surveillance and Statistics (2023–2024); FDA prescribing information — nirsevimab-alip (Beyfortus), palivizumab (Synagis), ribavirin; ACIP Recommendations for Use of Nirsevimab (MMWR 2023); Ralston SL et al. “Clinical Practice Guideline: The Diagnosis, Management, and Prevention of Bronchiolitis.” Pediatrics. 2014; Griffiths C et al. “Respiratory syncytial virus: infection, detection, and new options for prevention and treatment.” Clin Microbiol Rev. 2017.